Procter & Gamble Health has planned to source injections portfolio of its products from a contract manufacturer, hence the Company shall discontinue production of injections at its manufacturing plant in Goa effective September 30, 2023. The Company is outsourcing manufacturing of the injections portfolio with an intent to achieve cost efficiency and supply optimization.
The injections portfolio, procured from the Company’s manufacturing facility at Goa, accounted for revenue of Rs 102.92 crore during the financial year 2022-23, constituting 8.37% of the Company’s total revenue. Discontinuation of production at Company’s plant in Goa shall not have an impact on continuity of sale of injections by the Company, as the products will be sourced from a contract manufacturer.
Procter & Gamble Health is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |